Alvimopan monohydratePAM-OR antagonist CAS# 1383577-62-5 |
2D Structure
- Alvimopan
Catalog No.:BCC1347
CAS No.:156053-89-3
- Alvimopan dihydrate
Catalog No.:BCC1348
CAS No.:170098-38-1
- JDTic
Catalog No.:BCC1670
CAS No.:361444-66-8
- ADL5859 HCl
Catalog No.:BCC1265
CAS No.:850173-95-4
- Cebranopadol
Catalog No.:BCC1467
CAS No.:863513-91-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1383577-62-5 | SDF | Download SDF |
PubChem ID | 71587995 | Appearance | Powder |
Formula | C25H34N2O5 | M.Wt | 442.55 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid;hydrate | ||
SMILES | CC1CN(CCC1(C)C2=CC(=CC=C2)O)CC(CC3=CC=CC=C3)C(=O)NCC(=O)O.O | ||
Standard InChIKey | XSTFUWQLHMJPFG-NABRLNOVSA-N | ||
Standard InChI | InChI=1S/C25H32N2O4.H2O/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19;/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30);1H2/t18-,20-,25+;/m0./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Alvimopan monohydrate Dilution Calculator
Alvimopan monohydrate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2596 mL | 11.2982 mL | 22.5963 mL | 45.1926 mL | 56.4908 mL |
5 mM | 0.4519 mL | 2.2596 mL | 4.5193 mL | 9.0385 mL | 11.2982 mL |
10 mM | 0.226 mL | 1.1298 mL | 2.2596 mL | 4.5193 mL | 5.6491 mL |
50 mM | 0.0452 mL | 0.226 mL | 0.4519 mL | 0.9039 mL | 1.1298 mL |
100 mM | 0.0226 mL | 0.113 mL | 0.226 mL | 0.4519 mL | 0.5649 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Description: IC50 Value: 1.7 nM(Mu-type opioid receptor) [1] Alvimopan is a peripherally acting mu-opioid receptor (PAM-OR) antagonist for accelerating gastrointestinal recovery after surgery. in vitro: The dissociation rate of alvimopan from the micro opioid receptor (t(1/2)=30--44 min) was comparable to that of the long acting partial agonist buprenorphine (t(1/2)=44 min), but was slower than those of the antagonists naloxone (t(1/2)=0.82 min) and N-methylnaltrexone (t(1/2)=0.46 min) [2]. in vivo: Alvimopan did not significantly accelerate GI-3 compared with placebo [6 mg: hazard ratio (HR) = 1.20, p = 0.080; 12 mg: HR = 1.24, p = 0.038). However, after adjustment for significant covariates (sex/surgical duration), benefits were significant for both doses (6 mg: HR = 1.24, p = 0.037; 12 mg: HR = 1.26, p = 0.028). Alvimopan also significantly accelerated time to GI-2 (6 mg: HR = 1.37, p = 0.008; 12 mg: HR = 1.33, p = 0.018) and DCO (6 mg: HR = 1.31, p = 0.008; 12 mg: HR = 1.28, p = 0.015) [3]. Alvimopan (1 and 3 mg/kg) significantly reversed this delayed GI transit when administered 45 min prior to surgery. However, the effects of alvimopan were less pronounced when administered following surgery [4]. Toxicity:The most common treatment-emergent adverse events across all treatment groups were nausea, vomiting, and hypotension; the incidence of nausea and vomiting was reduced by 53 percent in thealvimopan 12-mg group [5]. Clinical trial: Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy. Phase 3
- BD 1047 dihydrobromide
Catalog No.:BCC6863
CAS No.:138356-21-5
- BD 1008 dihydrobromide
Catalog No.:BCC6674
CAS No.:138356-09-9
- CYM 9484
Catalog No.:BCC6238
CAS No.:1383478-94-1
- Hedycoronen A
Catalog No.:BCN7653
CAS No.:1383441-73-3
- Stearyl glycyrrhetinate
Catalog No.:BCN8486
CAS No.:13832-70-7
- ML 289
Catalog No.:BCC6343
CAS No.:1382481-79-9
- (RS)-(Tetrazol-5-yl)glycine
Catalog No.:BCC6599
CAS No.:138199-51-6
- H-β-HoPhe-OH
Catalog No.:BCC3240
CAS No.:138165-77-2
- 7-Methoxy-1-naphthylacetonitrile
Catalog No.:BCN2242
CAS No.:138113-08-3
- Agomelatine
Catalog No.:BCN2165
CAS No.:138112-76-2
- (R,R)-THC
Catalog No.:BCC7224
CAS No.:138090-06-9
- Acetylanonamine
Catalog No.:BCN2140
CAS No.:138079-62-6
- Boc-Arg(Tos)-OH
Catalog No.:BCC3067
CAS No.:13836-37-8
- Afzelechin-(4alpha->8)-epiafzelechin
Catalog No.:BCN7709
CAS No.:1383627-30-2
- Tinospinoside C
Catalog No.:BCN6925
CAS No.:1383977-51-2
- Irbesartan
Catalog No.:BCC2560
CAS No.:138402-11-6
- A 1070722
Catalog No.:BCC7933
CAS No.:1384424-80-9
- FK 888
Catalog No.:BCC5907
CAS No.:138449-07-7
- Ro 31-8220 Mesylate
Catalog No.:BCC4999
CAS No.:138489-18-6
- S-(+)-Marmesin
Catalog No.:BCN8288
CAS No.:13849-08-6
- 3-Oxopomolic acid
Catalog No.:BCN3485
CAS No.:13849-90-6
- Pomolic acid
Catalog No.:BCN6197
CAS No.:13849-91-7
- Tormentic acid
Catalog No.:BCN6198
CAS No.:13850-16-3
- 9-Hydroxycanthin-6-one
Catalog No.:BCN3105
CAS No.:138544-91-9
Gateways to clinical trials.[Pubmed:18389098]
Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):67-99.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prouse Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 101M, 3F8; Abatacept, ABT-263, Adalimumab, AG-7352, Agatolimod sodium, Alfimeprase, Aliskiren fumarate, Alvimopan hydrate, Aminolevulinic acid hexyl ester, Ammonium tetrathiomolybdate, Anakinra, Aripiprazole, AS-1404, AT-9283, Atomoxetine hydrochloride, AVE-1642, AVE-9633, Axitinib, AZD-0530; Becocalcidiol, Belotecan hydrochloride, Bevacizumab, BG-9928, BIBF-1120, BMS-275183, Bortezomib, Bosentan; Catumaxomab, Cetuximab, CHR-2797, Ciclesonide, Clevidipine, Cypher, Cytarabine/daunorubicin; Darifenacin hydrobromide, Darunavir, Denosumab, Desvenlafaxine succinate, Disufenton sodium, Duloxetine hydrochloride, Dutasteride; Eculizumab, Efalizumab, Eicosapentaenoic acid/docosahexaenoic acid, Eplerenone, Epratuzumab, Erlotinib hydrochloride, Escitalopram oxalate, Ethynylcytidine, Etravirine, Everolimus, Ezetimibe; Fulvestrant; Garenoxacin mesilate, Gefitinib, Gestodene; HI-164, Hydralazine hydrochloride/isosorbide dinitrate; Icatibant acetate, ICX-RHY, Idraparinux sodium, Indacaterol, Ispronicline, Ivabradine hydrochloride, Ixabepilone; KB-2115, KW-2449; L-791515, Lapatinib ditosylate, LGD-4665, Licofelone, Liposomal doxorubicin, Lisdexamfetamine mesilate, Lumiracoxib; Methoxy polyethylene glycol-epoetin-beta, Miglustat, Mipomersen sodium, Mitumprotimut-T, MK-0822A, MK-0974; Nelarabine; Obatoclax mesylate, Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide; Paliperidone, Palonosetron hydrochloride, Panitumumab, Pegfilgrastim, Peginterferon alfa-2a, Pemetrexed disodium, Perospirone hydrochloride, Pertuzumab, Pimecrolimus, Pitrakinra, Pixantrone maleate, Posaconazole, Pregabalin; Quercetin; RALGA, Raltegravir potassium, Ranelic acid distrontium salt, rhHistone 1.3, Rimonabant, Rivaroxaban, Rosuvastatin calcium, RTS,S/SBAS2; Satraplatin, SNDX-275, Sodium butyrate, Solifenacin succinate, Sorafenib, SU-14813, Sunitinib malate; Tadalafil, Tafenoquine succinate, Tamatinib fosdium, Taxus, Telbivudine, Telmisartan/hydrochlorothiazide, Temsirolimus, Tiotropium bromide, Tipranavir, Tocilizumab, Trabectedin, Tramadol hydrochloride/acetaminophen; Ulipristal acetate, Uracil, Ursodeoxycholyltaurine; Valdecoxib, Vardenafil hydrochloride hydrate, Varenicline tartrate, Vildagliptin, Vinflunine, Vitespen, Vorinostat; ZK-EPO, Zoledronic acid monohydrate.